Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus

HBsAg-1018 induced significantly higher seroprotection than HBsAg-Eng in CKD patients with diabetes.